You need to register to watch content!

Course Information

Course Instructor

Author
 

AML ALL EU 2023

€1,000.00

Registration fee

Complimentary coupon code for supporters can be added at checkout.

 
Continue

Opening introduction: Ryan Fitzpatrick, CEO, MD Education

Opening introduction: Ryan Fitzpatrick, CEO, MD Education

Session I: Fit AML, Chaired by: Charlie Craddock

Research and progress in AML, Hagop Kantarjian – MD Anderson Cancer Center, Houston, Texas
MRD and treatment decision making in Fit AML, Felicitas Thol – Hannover Medical School, Hannover, Germany
Genomics and treatment decision making in Fit adult AML, Paresh Vyas – University of Oxford, UK
Optimising front line management of Fit AML, Alessandro Isidori – Marche Nord Hospital, Pesaro, Italy
Which patients with high-risk AML should we transplant and how?, Charlie Craddock – Queen Elizabeth Hospital, Birmingham, UK
Session 1  Panel Discussion

Session II: Chaired by: Naval Daver

Optimizing frontline therapy for FLT3 mutated AML patients eligible for intensive chemotherapy, Gesine Bug – University Hospital Frankfurt, Germany
Treatment of APML in 2023, Steve Knapper – Cardiff University, UK
Addressing inequity of outcomes and accessing patients with AML, Pramila Krishnamurthy – King’s College Hospital NHS, Foundation Trust
Mechanisms of resistance and novel combinations with venetoclax based therapies in AML, Naval Daver – MD Anderson Cancer Center, Houston, Texas
Session 2  Panel Discussion
Session 2 Independent Discussion supported by Astellas

Session III: Chaired by: Alessandro Isidori

Research and progress in ALLL, Hagop Kantarjian – MD Anderson Cancer Center, Houston, Texas
Novel approaches to treatment of TP53 mutated AML, Emma Searle – Christie Hospital, Manchester, UK
Menin inhibitors, Eunice Wang – Roswell Park Comprehensive Cancer Center, New York, USA
Immunotherapeutic strategies in AML, Sara Ghorashian – University College London
Optimising transplant outcome, Alessandro Rambaldi – University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Session 3 Panel Discussion

Session IV: Chaired by: Charlie Craddock & Naval Daver

Yes to Venetoclax, Victoria Potter – King’s College Hospital NHS Foundation Trust, London, UK
Yes to Venetoclax, Alessandro Rambaldi – University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
No to Venetoclax, Stéphane de Botton, – Tor Vergata University of Rome, Italy
No to Venetoclax, Jurjen Versluis – Erasmus University, Rotterdam
S4 Debate Discussion
Optimal use of Venetoclax in unfit adults in 2023, Jessica Altman – Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
Optimal use of Venetoclax in unfit adults in 2023, Priyanka Mehta – University Hospitals Bristol and Weston NHS Foundation Trust, UK
S4 Panel Discussion

Session V: Chaired by: Elias Jabbour & Anna Castleton

Research and progress in ALL, Elias Jabbour – MD Anderson Cancer Center, Houston, Texas
Progress and open questions in treatment of AYA ALL, Christina Peters – St. Anna Children’s Cancer Research Institute, Vienna, Austria
Unmet needs in pediatric ALL, David O’Connor – Great Ormond Street Hospital for Children, UK
MRD in ALL: Clinical Consequences – When and How?, Nicola Gokbuget – University Hospital Frankfurt, Germany
Session 5 Panel Discussion

Session VI: Chaired by: Christina Peters & Cristina Papayannidis

Antibodies in MRD+ ALL, Cristina Papayannidis – Universita di Bologna Italy
Antibodies as “Bridges to SCT” in Ph neg ALL, Sabine Kayser – Medical Faculty Mannheim, Heidelberg University, Germany
How I treat Ph positive ALL in 2023, Elias Jabbour – MD Anderson Cancer Center, Houston, Texas
Session 6 Panel Discussion
Yes for all patients, Phillippe Rousselot – Hôpital de Versailles, France
No for all patients, Sabina Chiaretti – Sapienza University of Rome, Italy
S6 Debate
S6 Independent discussion supported by Jazz

Session VII: Chaired by: Sabina Chiaretti & Elias Jabbour

Optimizing first line therapy in elderly Ph neg B- ALL, Matthias Stelljes – Universitätsklinikum Münster, Germany
Genetics of Ph like ALL, Ilaria Iacobucci – St. Jude Children’s Research Hospital, USA
Treatment strategies for Ph like ALL, Anna Castleton – The Christie NHS Foundation Trust, Manchester, UK
Precision Medicine for T-ALL, Jan Cools – KU Leuven, Belgium, Germany
Session 7 Panel Discussion

Session VIII: Chaired by: Sridhar Chaganti & Cristina Papayannidis

Menin inhibitors in r-KMT2A ALL, Cristina Papayannidis – Universita di Bologna Italy
CAR-T in ALL: present and perspectives, Claire Roddie – University College London, UK
Metabolism and ALL: therapeutic implications, Giovanni Martinelli – IRST IRCCS, Meldola FC, Italy
When not to transplant in newly diagnosed ALL, Sridhar Chaganti – Queen Elizabeth Hospital Birmingham, UK
Session 8 Panel Discussion

AML-ALL EU Focus 2023

It is our pleasure to invite you to participate in this one-of-a-kind event.

If you need additional information please contact us at: office@md-education.com

MD Education
4/4a Bloomsbury Square,
London, WC1A 2RP

MD Education USA LLC
4600 140th Avenue North Suite,
180 Clearwater, Florida 33762